Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Name:
Stefanachi et al_final.pdf
Size:
820.6Kb
Format:
PDF
Description:
original manuscript
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Stefanachi, AngelaHanke, Nina
Pisani, Leonardo
Leonetti, Francesco
Nicolotti, Orazio
Catto, Marco
Cellamare, Saverio
Hartmann, Rolf W
Carotti, Angelo
Issue Date
2015-01-07
Metadata
Show full item recordAbstract
Diseases triggered by an abnormally high level of cortisol (hypercortisolism), such as the Cushing's and metabolic syndromes, could be successfully tackled by inhibitors of CYP11B1, a steroidal cytochrome P450 enzyme that catalyzes the last hydroxylation step of the cortisol biosynthesis. Structural optimization of 7-(benzyloxy)-4-(1H-imidazol-1-ylmethyl)-2H-chromen-2-one 2, a selective aromatase inhibitor, afforded the 4-(1H-imidazol-1-ylmethyl)-7-{[3-(trifluoromethoxy)benzyl]oxy}-2H-chromen-2-one 7, with improved inhibitory potency at human CYP11B1 (IC50 = 5 nM) and an enhanced selectivity over human CYP11B2 (SIB = 25) compared to lead compound 2 (IC50 = 72 nM, SIB = 4.0) and metyrapone (IC50 = 15 nM, SIB = 4.8), a non-selective drug used in the therapy of the Cushing's syndrome. Structure-activity relationship studies allowed the design and optimization of a novel series of potent and selective compounds, that can be regarded as open analogues of 2H-chromen-2-one derivatives. Compound 23, 2-(1H-imidazol-1-yl)-1-(4-{[3(trifluoromethoxy)benzyl]oxy}phenyl) ethanone, was the most interesting inhibitor of the series displaying a high potency at CYP11B1 (IC50 = 15 nM), increased selectivities over CYP11B2 (SIB = 33), CYP19 (SIB = 390) and CYP17 (5% inhibition at 2.5 μM concentration).Citation
Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase. 2015, 89:106-14 Eur J Med ChemAffiliation
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), PO Box 15 11 50, D-66041 Saarbrücken, Germany.PubMed ID
25462231Type
ArticleLanguage
enISSN
1768-3254ae974a485f413a2113503eed53cd6c53
10.1016/j.ejmech.2014.10.021
Scopus Count
The following license files are associated with this item:
Related articles
- Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
- Authors: Grombein CM, Hu Q, Rau S, Zimmer C, Hartmann RW
- Issue date: 2015 Jan 27
- Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.
- Authors: Yin L, Lucas S, Maurer F, Kazmaier U, Hu Q, Hartmann RW
- Issue date: 2012 Jul 26
- N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
- Authors: Zimmer C, Hafner M, Zender M, Ammann D, Hartmann RW, Vock CA
- Issue date: 2011 Jan 1
- Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.
- Authors: Gobbi S, Hu Q, Foschi G, Catanzaro E, Belluti F, Rampa A, Fimognari C, Hartmann RW, Bisi A
- Issue date: 2019 May
- Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.
- Authors: Hu Q, Yin L, Ali A, Cooke AJ, Bennett J, Ratcliffe P, Lo MM, Metzger E, Hoyt S, Hartmann RW
- Issue date: 2015 Mar 12